Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Blood ; 112(7): 2906-16, 2008 Oct 01.
Article in English | MEDLINE | ID: mdl-18591385

ABSTRACT

Overexpression of antiapoptotic members of the Bcl-2 family is observed in approximately 80% of B-cell lymphomas, contributing to intrinsic and acquired drug resistance. Nullifying the antiapoptotic influence of these proteins can potentially overcome this resistance, and may complement conventional chemotherapy. ABT-737 is a BH3-only mimetic and potent inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X(L), and Bcl-w. In vitro, ABT-737 exhibited concentration-dependent cytotoxicity against a broad panel of lymphoma cell lines including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). ABT-737 showed synergism when combined with the proteasome inhibitors bortezomib or carfilzomib in select lymphoma cell lines and induced potent mitochondrial membrane depolarization and apoptosis when combined with either. ABT-737 plus bortezomib also induced significant apoptosis in primary samples of MCL, DLBCL, and chronic lymphocytic leukemia (CLL) but no significant cytotoxic effect was observed in peripheral blood mononuclear cells from healthy donors. In severe combined immunodeficient beige mouse models of MCL, the addition of ABT-737 to bortezomib enhanced efficacy compared with either drug alone and with the control. Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies.


Subject(s)
Antineoplastic Agents/pharmacology , Biphenyl Compounds/pharmacology , Enzyme Inhibitors/pharmacology , Lymphoma/enzymology , Lymphoma/pathology , Molecular Mimicry/drug effects , Nitrophenols/pharmacology , Proteasome Inhibitors , Sulfonamides/pharmacology , Animals , Boronic Acids/pharmacology , Bortezomib , Cell Death/drug effects , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm/drug effects , Drug Synergism , Health , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukocytes, Mononuclear/drug effects , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Mantle-Cell/pathology , Membrane Potential, Mitochondrial/drug effects , Mice , Microscopy, Confocal , Piperazines/pharmacology , Proto-Oncogene Proteins c-bcl-2/metabolism , Pyrazines/pharmacology , Tissue Donors , Xenograft Model Antitumor Assays
2.
J Biol Chem ; 281(15): 10188-95, 2006 Apr 14.
Article in English | MEDLINE | ID: mdl-16452470

ABSTRACT

Phosphorylation (P-) of cAMP-response element-binding protein (CREB) by protein kinase A or mitogen-activated protein kinases was implicated in mediating the increased tyrosine hydroxylase (TH) gene expression after prolonged exposure to nicotine in vivo and in cell culture. We examined the time course and signaling pathways for phosphorylation of CREB and possible involvement of ATF-2. Treatment of PC12 cells with 200 microm nicotine triggered rapid but transient elevation of P-CREB followed by a second sustained rise after 2-5 h of continuous nicotine. In contrast, ERK1/2 was only phosphorylated with short term nicotine exposure. MEK inhibitor U0126 abolished nicotine-induced rise in P-ERK1/2, but not P-CREB, nor did it inhibit nicotine-evoked elevation in TH promoter activity, indicating that ERK1/2 was not needed for induction of TH gene expression by nicotine. In contrast, protein kinase A inhibitor H-89 or Ca(2+)/calmodulin-activated protein kinase inhibitor KN-93 reduced the nicotine-triggered rise in P-CREB and TH promoter activity. There was a delayed elevation of P-ATF-2 after 1 h of nicotine treatment, accompanied by increased ATF-2 protein. Upstream kinase JNK, but not p38, was phosphorylated especially after 5 min to 2 h of nicotine exposure. To examine the requirement for CREB and ATF-2, cells were transfected with dominant negative forms of ATF-2 or CREB. Both reduced the basal TH promoter activity and the response to nicotine. Knockdown of ATF-2 or CREB with siRNA did not alter basal TH promoter activity or mRNA but greatly attenuated the response to nicotine. The results suggest that both ATF-2 and CREB mediate activation of TH gene transcription by nicotine.


Subject(s)
Activating Transcription Factor 2/metabolism , Cyclic AMP Response Element-Binding Protein/metabolism , Gene Expression Regulation, Enzymologic , Nicotine/pharmacology , Transcription, Genetic , Tyrosine 3-Monooxygenase/metabolism , Animals , Blotting, Western , Butadienes/pharmacology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Genes, Dominant , Isoquinolines/pharmacology , Luciferases/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Models, Genetic , Nitriles/pharmacology , PC12 Cells , Phosphorylation , RNA, Small Interfering/metabolism , Rats , Sulfonamides/pharmacology , Time Factors , Transfection , Tyrosine 3-Monooxygenase/genetics
3.
Eur J Pharmacol ; 506(1): 37-46, 2004 Dec 03.
Article in English | MEDLINE | ID: mdl-15588622

ABSTRACT

The effect of epibatidine on regulation of [Ca2+]i and tyrosine hydroxylase (TH) transcription was examined. Epibatidine triggers a biphasic rise in [Ca2+]i in PC12 cells similar to that observed with nicotine. There was an immediate transient increase in [Ca2+]i and a subsequent sustained second elevation. In contrast to nicotine, the epibatidine-triggered increase in [Ca2+]i was independent of activation of alpha7 nicotinic acetylcholine receptors, as it was not altered by either methyllycaconitine or alpha-bungarotoxin. The second [Ca2+]i elevation involves calcium release from intracellular stores and is inhibited by dantrolene or xestospongin C. Epibatidine, like nicotine, elevated TH promoter driven reporter transcription, mostly mediated by the cyclic-AMP responsive motifs. Elevation in TH promoter activity requires Ca2+ and cAMP since it is inhibited by 1,2-bis(o-Aminophenoxy)ethane-N,N,N',N'-tetraacetic Acid Tetra (acetoxymethyl ester) (BAPTA-AM) or 2',5'-dideoxyadenosine (DDA). The results reveal that epibatidine can elevate [Ca2+]i in an alpha7 independent manner and nevertheless induce TH transcription.


Subject(s)
Aconitine/analogs & derivatives , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Calcium/metabolism , Dideoxyadenosine/analogs & derivatives , Egtazic Acid/analogs & derivatives , Nicotine/pharmacology , Pyridines/pharmacology , Tyrosine 3-Monooxygenase/genetics , Aconitine/pharmacology , Animals , Bungarotoxins/pharmacology , Dideoxyadenosine/pharmacology , Dose-Response Relationship, Drug , Egtazic Acid/pharmacology , Luciferases/genetics , Luciferases/metabolism , PC12 Cells , Promoter Regions, Genetic/genetics , Rats , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Time Factors , Transcription, Genetic/drug effects
4.
Neuroreport ; 15(7): 1177-81, 2004 May 19.
Article in English | MEDLINE | ID: mdl-15129169

ABSTRACT

We examined the effect of butyrate on neurotransmitter-related gene expression and calcium homeostasis in PC12 cells. Pretreatment with Ca2+ chelators (EGTA or BAPTA-AM) attenuated the butyrate-triggered accumulation of TH and ppEnk mRNA indicating that Ca2+ plays a role in butyrate-induced regulation of neuronal genes. Butyrate alone did not alter intracellular Ca2+ levels as determined by Fura-PE3 fluorescence; however, pretreatment with butyrate (18-24 h) reduced the first Ca2+ peak and prevented the second sustained rise in [Ca2+]i as induced by nicotine or ryanodine. In contrast, butyrate had no effect on Ca2+ transients when added shortly before or during nicotine or ryanodine stimulation. These results suggest that chronic butyrate exposure can modulate cell responses by affecting intracellular Ca2+ signaling.


Subject(s)
Butyrates/pharmacology , Calcium/physiology , Gene Expression Regulation/drug effects , Neurotransmitter Agents/biosynthesis , Animals , Gene Expression Regulation/physiology , Intracellular Fluid/drug effects , Intracellular Fluid/metabolism , Intracellular Fluid/physiology , Neurotransmitter Agents/metabolism , PC12 Cells , Rats
5.
Ann N Y Acad Sci ; 971: 39-44, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12438086

ABSTRACT

It is important to determine how the signaling pathways for the short-term effects of nicotine (catecholamine secretion, phosphorylation of tyrosine hydroxylase) differ from those required for changes in gene expression. Our aim was to distinguish the pathways involved in short- and long-term nicotinic stimulation. PC12 cells were treated with several concentrations of nicotine from 10 micro M to 1 mM. All elicited a rapid and transient rise in [Ca(2+)](i), which was concentration dependent. After several minutes of continued exposure, a second smaller sustained rise in [Ca(2+)](i) was only observed with intermediate concentrations of nicotine (50-200 micro M). This sustained rise was not observed in cells pretreated with alpha-bungarotoxin (alpha-BTX). alpha-BTX also prevented the elevation of tyrosine hydroxylase mRNA by nicotine. The effects of brief and prolonged treatment with nicotine on the signaling pathways involved in changes in [Ca(2+)](i) and induction of tyrosine hydroxylase gene expression are summarized. The results indicate that nicotine may elicit different signaling pathways depending on the concentration. The sustained elevation of [Ca(2+)](i) via activation of alpha7 nAChRs is proposed as the mechanism leading to increased tyrosine hydroxylase gene expression.


Subject(s)
Calcium/metabolism , Nicotine/pharmacology , Tyrosine 3-Monooxygenase/biosynthesis , Tyrosine 3-Monooxygenase/genetics , Animals , Bungarotoxins/metabolism , Bungarotoxins/pharmacology , Gene Expression Regulation , Nicotinic Agonists/pharmacology , PC12 Cells , RNA, Messenger/metabolism , Rats , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...